A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis
← catalyst calendarSponsored by Hepion Pharmaceuticals, Inc. (industry) · HEPA — their whole pipeline →.
Phase
Phase 2
Status
Unknown status
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
120actual
Sites
41
Countries
France, Mexico, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-10-15 | actual | When the study began enrolling |
| Primary completion | May 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2022-06-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-05-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Nonalcoholic Steatohepatitis (NASH)
- Fibrosis, Liver
- NAFLD
Interventions
- Drug: Rencofilstat — also filed as CRV431
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFProportion of subjects with improvement in fibrosis by at least 1 stage (NASH CRN system) OR NASH resolution without worsening of fibrosis.
measured dosing period of 1 year with 1 month observation and follow up period
Permalink · HEPA's whole pipeline · Catalyst calendar · Every registered study · What changed